Clinical Conversations: SICP: Impact and Challenges of Risk Evaluation and Mitigation Strategy (REMS) Programs in Practice
The US Food and Drug Administration (FDA) implemented Risk Evaluation and Mitigation Strategy (REMS) programs to ensure benefits outweigh the safety risks of particular medications. With over 60 medications with REMS programs and varying requirements for each, operationalizing to comply with requirements can be challenging. In this podcast, we talk about some of those challenges and how to operationalize recommendations for those who routinely see these medications in practice, as well as for those who come across them sporadically.
The information presented during the podcast reflects solely…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.